IL-23-Specific Antibody Ups Response in Anti-TNF-Refractory Crohn ' s

(MedPage Today) -- Subcutaneous risankizumab also looks promising for maintaining remission
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news